Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Ai Patient Safety topic
No spam. Unsubscribe anytime.
Board committee flags patient safety risks from consumer use of AI, plans one‑page guidance
Summary
The committee examined risks when patients rely on AI for medication guidance — misinformation, automation bias and missing medical context — and supported developing a one‑page fact sheet advising patients to consult pharmacists.
The Communication & Public Education Committee discussed potential patient safety risks associated with consumers using artificial intelligence tools in place of pharmacist consultations.
Staff summarized documented risks: AI language models can produce inaccurate or fabricated medication instructions (so‑called "hallucinations"), lack access to a patient’s full medical history and allergies, and may produce inconsistent answers across models. Chair Nicole Thibo emphasized concern that patients might skip pharmacist consultations in favor of AI, potentially leading to harm.
Members and public commenters urged a short, consumer‑facing fact sheet that explains AI’s limits, cautions patients about automation bias and misinformation, and directs patients to consult a licensed pharmacist for individualized dosing, interaction checks and sensitive questions. Members also recommended linking the AI guidance to consultation and translation materials. Several speakers highlighted equity and data‑bias concerns: AI training data are skewed toward users who share more information, which can deepen disparities for underrepresented groups.
The committee agreed to proceed with a one‑page educational resource and to monitor legislative activity on AI; staff will return with draft language and options for distribution.
